Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Q-linea AB ( (SE:QLINEA) ).
Q-linea has expanded its Middle East footprint by shipping two ASTar instruments to hospitals in Saudi Arabia, where local distributor AMICO will oversee installation and evaluations ahead of anticipated clinical use in 2026. These units build on earlier evaluation deployments in Kuwait and the UAE, reflecting stronger regional demand for rapid antibiotic susceptibility testing as health systems seek to enhance sepsis management and antimicrobial stewardship.
The new installations in leading hospital systems in Riyadh and Jeddah are expected to inform adoption decisions by Saudi Arabia’s Ministry of Health, potentially paving the way for broader national rollout. With the first ASTar in the region forecast to enter routine use in the second quarter of 2026 and additional sites to follow, the move could significantly bolster Q-linea’s commercial position in the Gulf while supporting AMICO’s strategy to accelerate access to advanced in vitro diagnostic technologies.
The most recent analyst rating on (SE:QLINEA) stock is a Hold with a SEK22.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
More about Q-linea AB
Q-linea AB is a Swedish infection diagnostics company focused on rapid antibiotic susceptibility testing for serious infections such as sepsis. Its flagship product, the fully automated ASTar system, delivers phenotypic test results from positive blood cultures in about six hours, enabling quicker optimal antibiotic treatment and supporting efforts to combat antimicrobial resistance. Listed on Nasdaq Stockholm and founded in 2008, the company targets hospitals and laboratories seeking to improve clinical outcomes and reduce healthcare costs through faster, precision diagnostics.
YTD Price Performance: -9.76%
Average Trading Volume: 12,035
Technical Sentiment Signal: Sell
Current Market Cap: SEK419.1M
For a thorough assessment of QLINEA stock, go to TipRanks’ Stock Analysis page.